ATAI Investor Presentation Deck
October 2022, 36 slides
  1. ATAI
  2. Related Decks
  3. Investor Presentation Decks
company overview company overview healing mental health disorders so that everyone everywhere can live a more life | ATAI
| ATAI
mental health disorders have become one of global health burdens depression rates of us adults saw a increase since the onset of the covid pandemic as a response to the technical risks associated with drug development focuses on compound classes with prior evidence in humans and utilizes a decentralized drug development process active programs drug and discovery programs and enabling technologies focusing on potentially disease modifying therapies validation of operating model of compass pathways and validating license deal between perception we have a strong cash position of as of june and access to up to from term loan facility with giving cash runway into life sciences healing so that everyone everywhere can live more life | ATAI
founder chairman brand founder founder the team has collectively led through regulatory approval applications a founder led aiming to develop differentiated treatments for patients suffering from mental health disorders | ATAI
our objective achieve clinically meaningful and sustained change in patients diagnosed with mental health disorders key pillars rapid acting intervention focus ongoing support focus precision mental health focus and generation compounds that result in rapid acting improvement of mental health disorders additional care that is provided to patients before during and after initial treatment interventions the identification of patient sub types using biological and digital achieving through a combined approach | ATAI
we will deliver on our strategy through a robust pipeline with drug development programs across several mental health indications with large unmet need | ATAI
the platform enables improved probabilities of success across the pipeline via decentralized drug development entrepreneurial teams and matrix framework | ATAI
milestone highlights in anticipated catalysts across we will build on recent success by delivering several meaningful our key programs | ATAI
issuer ticker life sciences market capitalization outstanding shares cash cash equivalents million as of june access to up to from a term loan facility with capital well financed to fund planned operations into we have runway | ATAI
depression | ATAI
urgent need for innovation inadequate response rate slow onset of treatment effect long term side effects approvals since depression | ATAI
summary phase trial showed a rapid sustained reduction in depressive symptoms | ATAI
may increase patient accessibility by reducing patient and clinic time commitment | ATAI
we aim to develop as a rapid acting with potential for at home use | ATAI
in preclinical models higher potency longer lasting effect and lower potential for abuse | ATAI
phase data dosing showed minimal to no | ATAI
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
depression positioning and landscape programs are designed to be differentiated from one another and from competitors | ATAI
cognitive associated with schizophrenia | ATAI
huge need for development lost life expectancy low treatment rate cognitive impairment is very common approvals for schizophrenia | ATAI
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by episodic learning and memory deficits no approved treatment a risked excellent tolerability | ATAI
summary has previously shown pro cognitive effects in human clinical studies | ATAI
low doses enhanced learning and memory verbal learning delayed recall dose phase exploratory patients dose additionally a study in of also showed statistically significant positive cognitive signals | ATAI
phase a study showed wide spread beneficial changes | ATAI
schizophrenia landscape unique pharmacology acute cognitive benefit and excellent tolerability differentiate it from the current standard of care available to schizophrenia patients | ATAI
anxiety | ATAI
massive unaddressed need gad sufferers in the us low treatment rate anxiety depression are complimentary limited treatment options | ATAI
has the potential for like rapid onset efficacy with improved safety and tolerability | ATAI
there is an unmet need in gad for therapies with rapid onset high efficacy and minimal side effects can fill generalized anxiety disorder favorable safety profile | ATAI
substance use disorder | ATAI
an ongoing pandemic number of sufferers in us high relapse rates drug overdose deaths increase treatment options for | ATAI
a single dose of showed potential for sustained reductions in cravings in dependent patients | ATAI
summary could potentially become a paradigm shifting therapy for use disorder current standard of care for is medication therapy requiring substitutes that carry significant side effects current strategies for withdrawal support have high rates of relapse has the potential to the first best in class treatment minimizing risk | ATAI
enabling tech | ATAI
introspect our formulation stratification companies provide an additional avenue of growth innovation to the platform | ATAI
brand life sciences watching my best friend and business partner suffer being let down by existing treatments and finally finding comfort in therapies was all the inspiration i needed to commit my to this cause | ATAI
See More
ATAI
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Anxiety
Mental health
Drug development
Life science
Recent decks by ATAI
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
See all presentations by ATAI (13 decks)
Related decks
Comera
SPAC
January 2022
MindMed
Investor Presentation
April 2021
Teknova
IPO
June 2021
Neumora Therapeutics
IPO
September 2023
AbCellera
Investor Conference
May 2022
Talkspace
Results
February 2023
Sharecare
SPAC
February 2021
Comera
Investor Presentation
December 2023
Recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Comera
SPAC
January 2022
MindMed
Investor Presentation
April 2021
Teknova
IPO
June 2021
Neumora Therapeutics
IPO
September 2023
AbCellera
Investor Conference
May 2022
Talkspace
Results
February 2023
Sharecare
SPAC
February 2021
Comera
Investor Presentation
December 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io